We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

707 hedge funds and large institutions have $38.8B invested in Alexion Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 66 funds opening new positions, 241 increasing their positions, 295 reducing their positions, and 102 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more capital invested

Capital invested by funds: $31.3B → $38.8B (+$7.56B)

10% more funds holding in top 10

Funds holding in top 10: 70 → 77 (+7)

6% less funds holding

Funds holding: 752 → 707 (-45)

18% less repeat investments, than reductions

Existing positions increased: 241 | Existing positions reduced: 295

35% less first-time investments, than exits

New positions opened: 66 | Existing positions closed: 102

73% less call options, than puts

Call options by funds: $108M | Put options by funds: $402M

Holders
707
Holders Change
-45
Holders Change %
-5.98%
% of All Funds
12.31%
Holding in Top 10
77
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+10%
% of All Funds
1.34%
New
66
Increased
241
Reduced
295
Closed
102
Calls
$108M
Puts
$402M
Net Calls
-$294M
Net Calls Change
-$230M

Top Buyers

1
UOC
UBS O'Connor
Illinois
+$491M
2
Millennium Management
Millennium Management
New York
+$391M
3
FCM
Farallon Capital Management
California
+$332M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$245M
5
DKCM
Davidson Kempner Capital Management
New York
+$242M

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$611M
2
SC
Sculptor Capital
New York
-$247M
3
BG
Bellevue Group
Switzerland
-$222M
4
PC
Paulson & Co
New York
-$214M
5
Barclays
Barclays
United Kingdom
-$194M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.74B +$137M +798,317 +4%
BlackRock
2
BlackRock
New York
$3.21B -$9.39M -54,688 -0.3%
State Street
3
State Street
Massachusetts
$1.84B +$26.8M +156,274 +2%
FCM
4
Farallon Capital Management
California
$1.42B +$332M +1,932,500 +33%
HI
5
HBK Investments
Texas
$1.21B +$150M +875,000 +15%
DKCM
6
Davidson Kempner Capital Management
New York
$1.01B +$242M +1,409,202 +35%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$962M +$171M +995,635 +23%
PCM
8
Pentwater Capital Management
Florida
$906M +$111M +643,956 +15%
Millennium Management
9
Millennium Management
New York
$887M +$391M +2,276,841 +89%
UOC
10
UBS O'Connor
Illinois
$813M +$491M +2,861,349 +183%
Citigroup
11
Citigroup
New York
$809M +$193M +1,122,326 +34%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$760M +$30.1M +175,396 +4%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$740M +$86.1M +501,470 +14%
Citadel Advisors
14
Citadel Advisors
Florida
$597M +$128M +745,676 +30%
Renaissance Technologies
15
Renaissance Technologies
New York
$578M -$31M -180,600 -5%
Northern Trust
16
Northern Trust
Illinois
$512M +$13.4M +78,189 +3%
Barclays
17
Barclays
United Kingdom
$450M -$194M -1,128,398 -32%
CA
18
Capitolis Advisors
New York
$413M +$173M +1,005,666 +81%
Deutsche Bank
19
Deutsche Bank
Germany
$407M -$10.7M -62,309 -3%
Norges Bank
20
Norges Bank
Norway
$359M -$46.6M -271,531 -12%
Franklin Resources
21
Franklin Resources
California
$349M +$1.95M +11,357 +0.6%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$335M +$2.14M +12,491 +0.7%
OPU
23
Omni Partners US
California
$326M +$220M +1,283,115 New
Legal & General Group
24
Legal & General Group
United Kingdom
$323M +$54.1M +315,094 +22%
JP Morgan Chase
25
JP Morgan Chase
New York
$321M -$88.5M -515,586 -23%
1
2 3 4 5

ALXN Hedge Fund Activity: Q2 2021 in Review

707 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2021, worth a combined $38.8B — up 24% from $31.3B a quarter earlier.

Sellers outnumbered buyers: 102 funds closed out of ALXN and 66 opened new positions — a net loss of 36 holders — while 295 trimmed existing stakes and 241 added.

The largest buyer was UBS O'Connor, adding an estimated $491M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $611M sold.

  • 707 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2021, down from 752 in Q1 2021.
  • Funds reported $38.8B of Alexion Pharmaceuticals stock for Q2 2021, up 24% quarter-over-quarter.
  • 66 funds opened new Alexion Pharmaceuticals positions in Q2 2021 and 102 closed out, a net change of -36 holders.
  • The largest Alexion Pharmaceuticals buyer in Q2 2021 was UBS O'Connor, an estimated $491M added.
  • The largest Alexion Pharmaceuticals seller in Q2 2021 was Baker Bros. Advisors, an estimated $611M sold.

Based on aggregated 13F filings for Q2 2021.